Sanofi’s Tolebrutinib Delays Disability but Falls Short in Symptom Reduction

Sanofi's experimental drug for multiple sclerosis (MS), tolebrutinib, demonstrated its ability to delay disability progression in patients with nonrelapsing secondary progressive MS during a late-stage clinical trial. This form of MS is marked by a cessation of symptom relapses but continued disability accumulation, an area where there are currently no approved treatments. The success in delaying disability may pave the way for regulatory discussions about bringing the drug to market.

However, tolebrutinib failed to show significant improvements in reducing attack rates in patients with relapsing MS during other late-stage trials. These trials, which compared the drug to Sanofi's older MS medication, Aubagio, missed their primary goal but did indicate a notable delay in confirmed disability worsening. This mixed outcome could impact the drug’s market potential, particularly in treating nonrelapsing secondary progressive MS, where other drugs are sometimes used off-label.

Despite the setback, Sanofi’s stock rose by 2.8% following the announcement, reflecting cautious optimism about the drug's prospects. Sanofi is set to present the trial results at an upcoming medical conference, with additional data from a fourth late-stage trial expected next year. The results from these ongoing efforts will determine the future of tolebrutinib in the competitive MS treatment landscape.

Click here to read the original news story.